For instance, a phase II trial of dabrafenib, trametinib, and nivolumab in BRAF-mutated advanced melanoma patients showed an overall response rate 91% with relatively small proportion of patients that discontinued the study due to drug toxicity [19]. Here, BRAF is linked to melanoma.